Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
NEW ORLEANS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a se
Faruqi and Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 an
New York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between Decemb
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 05'th Nov 2025
Cytokinetics (CYTK) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.59. This compares to a loss of $1.36 per share a year ago.
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
04:00pm, Wednesday, 05'th Nov 2025
Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1
NEW YORK and NEW ORLEANS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they h
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
08:39pm, Tuesday, 04'th Nov 2025
NEW YORK , Nov. 4, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and M
New York, New York--(Newsfile Corp. - November 4, 2025) - WHY: Rosen Law Firm, a global investor rights law firm,
Cytokinetics to Participate in November Investor Conferences
04:00pm, Tuesday, 04'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following i
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
03:30pm, Tuesday, 04'th Nov 2025
LOS ANGELES , Nov. 4, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Cytokinetics, Inc
CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics
12:18pm, Tuesday, 04'th Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Cytokinetics To Contact Him Directly To Discuss Their Options
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
CYTK ALERT: Securities Fraud Class Action Launched Against Cytokinetics, Incorporated - November 17, 2025 Deadline
09:11am, Tuesday, 04'th Nov 2025
New York, New York--(Newsfile Corp. - November 4, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ:
